Silexion Therapeutics Corp financial data

Symbol
SLXN, SLXNW on Nasdaq
Location
Ramat Gan, Israel
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 242 %
Debt-to-equity 402 %
Return On Equity -650 %
Return On Assets -129 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3,126,642 shares -68%
Common Stock, Shares, Outstanding 3,126,642 shares -72%
Common Stock, Value, Issued 42,000 USD +41%
Weighted Average Number of Shares Outstanding, Basic 1,132,658 shares +25.2%
Weighted Average Number of Shares Outstanding, Diluted 1,132,658 shares +25.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 4,636,000 USD -33%
General and Administrative Expense 4,490,000 USD -76.4%
Operating Income (Loss) -9,126,000 USD +59%
Nonoperating Income (Expense) 117,000 USD -1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -9,243,000 USD +72.5%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -9,247,000 USD +72.5%
Earnings Per Share, Basic -81 USD/shares -99%
Earnings Per Share, Diluted -81 USD/shares -99%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 9,243,000 USD +3.7%
Other Assets, Current 47,000 USD -41.2%
Assets, Current 11,055,000 USD +2.6%
Property, Plant and Equipment, Net 26,000 USD -25.7%
Operating Lease, Right-of-Use Asset 442,000 USD
Assets 11,614,000 USD +2.8%
Accounts Payable, Current 946,000 USD +18.4%
Employee-related Liabilities, Current 721,000 USD +4.9%
Liabilities, Current 2,786,000 USD -22.2%
Operating Lease, Liability, Noncurrent 311,000 USD
Liabilities 4,637,000 USD -39.5%
Convertible Preferred Stock, Nonredeemable or Redeemable, Issuer Option, Value 0 USD -100%
Retained Earnings (Accumulated Deficit) -50,754,000 USD -22.1%
Stockholders' Equity Attributable to Parent 6,977,000 USD
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 6,977,000 USD
Liabilities and Equity 11,614,000 USD +2.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10,729,000 USD -7.2%
Net Cash Provided by (Used in) Financing Activities 8,624,000 USD +2%
Net Cash Provided by (Used in) Investing Activities -7,000 USD
Common Stock, Shares Authorized 9,000,000 shares -95.5%
Common Stock, Shares, Issued 3,126,642 shares -72%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares +100%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9,324,000 USD +3.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 40,000 USD
Deferred Tax Assets, Valuation Allowance 6,899,000 USD +25.3%
Deferred Tax Assets, Gross 7,021,000 USD +26.4%
Operating Lease, Liability 526,000 USD +2.1%
Depreciation -1,000 USD -81.8%
Payments to Acquire Property, Plant, and Equipment 7,000 USD -100%
Lessee, Operating Lease, Liability, to be Paid 636,000 USD
Property, Plant and Equipment, Gross 99,000 USD -25.6%
Operating Lease, Liability, Current 174,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 167,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One 165,000 USD
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure -7.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 110,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 172,000 USD
Deferred Tax Assets, Operating Loss Carryforwards 5,800,000 USD +31.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 132,000 USD
Operating Lease, Payments 56,000 USD
Additional Paid in Capital 57,689,000 USD +55.9%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 96,000 USD -99.3%